Bloomberg reports that Johnson & Johnson (NYSE: JNJ) aims to sell its DePuy Synthes Orthopaedics business for more than $20 billion.

Johnson & Johnson (NYSE:JNJ) is reportedly preparing for a potential sale of its orthopedics unit, DePuy Synthes, as it advances plans to separate the business. In 2011, the medtech giant acquired ...

Reports have emerged that Johnson & Johnson is preparing to sell its orthopedics unit, DePuy Synthes, which the company has been planning to spin out.

Johnson & Johnson MedTech has secured an FDA 510(k) clearance for its first robotically guided platform for spine surgery and has slated its commercial launch for the first half of next year. The ...

Since flapping its wings and leaving the General Electric nest at the start of this year, GE HealthCare has devoted much of its energy toward broadening its newly solo horizons. A newly struck ...

In late 2013, a $4 billion settlement program was announced by Johnson & Johnson. This settlement covers more than 8,000 plaintiffs with lawsuits or unfiled claims who have undergone revision surgery ...

BOSTON (Reuters) - Johnson & Johnson, which could face billions of dollars in costs over an artificial hip recall, is taking an unusual approach to managing the crisis -- one that could limit its ...

Indiana-based Biomet said it has made a binding offer to acquire the trauma business of Johnson & Johnson’s DePuy Orthopeadics subsidiary for approximately $280 million in cash. The deal is expected ...

Toxic hip implants used in thousands of operations in Britain were sold by a company which knew for at least three years that they could be dangerous, it was claimed today. Johnson & Johnson ...